Mark Kotter, bit.bio CEO

Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Bit.bio has lift­ed the cur­tain on its ear­ly pipeline of re­gen­er­a­tive med­i­cine can­di­dates made us­ing its cell pro­gram­ming tech­nol­o­gy, which is in­tend­ed to de­ter­min­is­ti­cal­ly trans­form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA